Quarterly ResultMay 7, 2026, 04:04 PM
BridgeBio Authorizes $500M Share Buyback; Q1 Revenue $194.5M
AI Summary
BridgeBio Pharma announced its first-quarter 2026 financial results, reporting total revenues of $194.5 million, a significant increase from $116.6 million in Q1 2025, primarily driven by $180.6 million in U.S. Attruby net product revenue. The company's Board authorized a share repurchase program of up to $500 million, citing the company's fully financed status and a perceived deep discount to intrinsic value. BridgeBio also provided positive updates on its pipeline, including the submission of an NDA for BBP-418 in LGMD2I/R9 and continued global expansion for Attruby with Brazil approval.
Key Highlights
- BridgeBio's Board authorized a share repurchase program of up to $500 million of common stock.
- Total first quarter revenues reached $194.5 million, up from $116.6 million in Q1 2025.
- U.S. Attruby net product revenue was $180.6 million, a substantial increase from $36.7 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $940.2 million as of March 31, 2026.
- Net loss attributable to common stockholders was $164.0 million, down from $167.4 million in Q1 2025.
- NDA for BBP-418 in LGMD2I/R9 submitted to FDA; on track for encaleret (1H 2026) and infigratinib (Q3 2026).
- Total operating costs and expenses increased to $300.5 million from $221.0 million in Q1 2025.
- Attruby received approval from the Brazilian Health Regulatory Agency (ANVISA) on May 4, 2026.